Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0W7WV
|
|||
| Former ID |
DNC005981
|
|||
| Drug Name |
L-869298
|
|||
| Synonyms |
L-869298; UNII-2I921E370K; CHEMBL199015; 2I921E370K; MK-298; 362718-73-8; SCHEMBL3225083; (+)-L-869298; BDBM50174020; 2-Thiazolemethanol, 5-((1S)-1-(3-(cyclopropyloxy)-4-(difluoromethoxy)phenyl)-2-(1-oxido-3-pyridinyl)ethyl)-alpha,alpha-bis(trifluoromethyl)-; 3-[(S)-beta-[2-[1-Hydroxy-1-(trifluoromethyl)-2,2,2-trifluoroethyl]-5-thiazolyl]-3-(cyclopropyloxy)-4-(difluoromethoxy)phenethyl]pyridine 1-oxide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H18F8N2O4S
|
|||
| Canonical SMILES |
C1CC1OC2=C(C=CC(=C2)C(CC3=C[N+](=CC=C3)[O-])C4=CN=C(S4)C(C(F)(F)F)(C(F)(F)F)O)OC(F)F
|
|||
| InChI |
1S/C23H18F8N2O4S/c24-20(25)37-16-6-3-13(9-17(16)36-14-4-5-14)15(8-12-2-1-7-33(35)11-12)18-10-32-19(38-18)21(34,22(26,27)28)23(29,30)31/h1-3,6-7,9-11,14-15,20,34H,4-5,8H2/t15-/m0/s1
|
|||
| InChIKey |
YDLQPURWTSDWCC-HNNXBMFYSA-N
|
|||
| CAS Number |
CAS 362718-73-8
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phosphodiesterase 4A (PDE4A) | Target Info | Inhibitor | [1] |
| Phosphodiesterase 4B (PDE4B) | Target Info | Inhibitor | [1] | |
| Phosphodiesterase 4D (PDE4D) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Purine metabolism | |||
| cAMP signaling pathway | ||||
| Morphine addiction | ||||
| NetPath Pathway | IL5 Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| Pathwhiz Pathway | Purine Metabolism | |||
| Reactome | DARPP-32 events | |||
| G alpha (s) signalling events | ||||
| WikiPathways | G Protein Signaling Pathways | |||
| Myometrial Relaxation and Contraction Pathways | ||||
| Nuclear Receptors Meta-Pathway | ||||
| Opioid Signalling | ||||
| TSH signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Enantiomer discrimination illustrated by the high resolution crystal structures of type 4 phosphodiesterase. J Med Chem. 2006 Mar 23;49(6):1867-73. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.